Access the full text.
Sign up today, get DeepDyve free for 14 days.
Drago, Semino, Rampini, Rebora (1999)
Parvovirus B19 infection associated with acute hepatitis and a purpuric exanthemBritish Journal of Dermatology, 141
I. Schmidt, Johannes Blümel, H. Seitz, H. Willkommen, Johannes Löwer (2001)
Parvovirus B19 DNA in plasma pools and plasma derivativesVox Sanguinis, 81
T. Hall (1999)
BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT
J. Mori, Pamela Beattie, David Melton, Bernard Cohen, J. Clewley (1987)
Structure and mapping of the DNA of human parvovirus B19.The Journal of general virology, 68 ( Pt 11)
S. Dorsch, B. Kaufmann, U. Schaible, E. Prohaska, H. Wolf, S. Modrow (2001)
The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability.The Journal of general virology, 82 Pt 1
Coumau Coumau, Peynet Peynet, Harzic Harzic (1996)
Infection sévère à parvovirus B19 chéz un enfant hémophile A immunocompétent (severe parvovirus B19 infection in an immunocompetent child with hemophilia A).Arch Pediatr, 3
Wardeh, Mařík (1998)
Acute lung injury due to parvovirus pneumoniaJournal of Internal Medicine, 244
A. Azzi, S. Ciappi, K. Zakvrzewska, M. Morfini, G. Mariani, P. Mannucci (1992)
Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentratesAmerican Journal of Hematology, 39
T. Schwarz, S. Serke, A. Brunn, B. Hottenträger, D. Huhn, F. Deinhardt, M. Roggendorf (1992)
Heat stability of parvovirus B19: kinetics of inactivation.Zentralblatt fur Bakteriologie : international journal of medical microbiology, 277 2
Parvovirus B 19 : implications for
Giuseppe Longo, M. Luppi, M. Bertesi, L. Ferrara, G. Torelli, G. Emilia (1998)
Still's disease, severe thrombocytopenia, and acute hepatitis associated with acute parvovirus B19 infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 26 4
M. Williams, B. Cohen, A. Beddall, K. Pasi, P. Mortimer, F. Hill (1990)
Transmission of Human Parvovirus B19 by Coagulation Factor ConcentratesVox Sanguinis, 58
K. Umene, T. Nunoue (1995)
A new genome type of human parvovirus B19 present in sera of patients with encephalopathy.The Journal of general virology, 76 ( Pt 11)
E. Brojer, P. Grabarczyk, S. Łopaciuk, Z. Moraczewska, B. Żupańska (1999)
Prevalence of Human Parvovirus B19 DNA and IgG/IgM Antibodies in Polish Haemophilia PatientsVox Sanguinis, 77
E. Santagostino, P. Mannucci, A. Gringeri, A. Azzi, M. Morfini (1994)
Eliminating parvovirus B19 from blood productsThe Lancet, 343
A. Hemauer, A. Poblotzki, A. Gigler, P. Cassinotti, G. Siegl, Hans Wolf, S. Modrow (1996)
Sequence variability among different parvovirus B19 isolates.The Journal of general virology, 77 ( Pt 8)
A. Azzi, A. Azzi, Massirno Morfini, Massirno Morfini, P. Mannucci, P. Mannucci (1999)
The transfusion-associated transmission of parvovirus B19.Transfusion medicine reviews, 13 3
J. Johansen, L. Christensen, K. Zakrzewska, K. Carlsen, A. Hornsleth, A. Azzi (1998)
Typing of European strains of parvovirus B19 by restriction endonuclease analyses and sequencing: identification of evolutionary lineages and evidence of recombination of markers from different lineages.Virus research, 53 2
P. Roberts, H. Hart (2000)
Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates.Biologicals : journal of the International Association of Biological Standardization, 28 3
H. Rollag, G. Patou, J. Pattison, M. Degré, Stein Evensen, S. Frøland, A. Glomstein (1991)
Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools.Scandinavian journal of infectious diseases, 23 6
(2002)
ParBLÜMEL ET AL
Eiji Miyagawa, T. Yoshida, Hirohiko Takahashi, K. Yamaguchi, Tohko Nagano, Yoshiko Kiriyama, Kazuo Okochi, Hiroyuki Sato (1999)
Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity.Journal of virological methods, 83 1-2
E. Coumau, J. Peynet, M. Harzic, G. Beal, S. Castaigne, G. Leverger, P. Foucaud (1996)
Infection sévère à parvovirus B19 chez un enfant hémophile A immunocompétentArchives De Pediatrie, 3
J. Lefrère, M. Mariotti, I. Croix, J. Lerable, M. Thauvin, T. Burnouf, G. Folléa (1995)
Albumin batches and B19 parvovirus DNATransfusion, 35
E. Coumau, J. Peynet, M. Harzic, G. Beal, S. Castaigne, G. Leverger, P. Foucaud (1996)
[Severe parvovirus B19 infection in an immunocompetent child with hemophilia A].Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 3 1
G. Enders, J. Dötsch, J. Bauer, W. Nützenadel, H. Hengel, D. Haffner, G. Schalasta, K. Searle, K. Brown (1998)
Life-threatening parvovirus B19-associated myocarditis and cardiac transplantation as possible therapy: two case reports.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 26 2
A. Eis-Hübinger, J. Oldenburg, H. Brackmann, B. Matz, K. Schneweis (1996)
The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population.Zentralblatt fur Bakteriologie : international journal of medical microbiology, 284 2-3
E. Santagostino, P. Mannucci, A. Gringeri, A. Azzi, M. Morfini, R. Musso, R. Santoro, M. Schiavoni (1997)
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.Transfusion, 37 5
J. Blümel, I. Schmidt, H. Willkommen, J. Löwer (2002)
Inactivation of parvovirus B19 during pasteurization of human serum albuminTransfusion, 42
K. Brown, N. Young, B. Alving, L. Barbosa (2001)
Parvovirus B19: implications for transfusion medicine. Summary of a workshopTransfusion, 41
A. Eis-Hübinger, U. Sasowski, H. Brackmann (1999)
Parvovirus B19 DNA Contamination in Coagulation Factor VIII ProductsThrombosis and Haemostasis, 81
K. Peerlinck, P. Goubau, R. Reybrouck, J. Desmyter, J. Vermylen (1995)
Parvovirus B19 Antibodies in Patients with Haemophilia AThrombosis and Haemostasis, 73
R. Shade, M. Blundell, S. Cotmore, P. Tattersall, C. Astell (1986)
Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisisJournal of Virology, 58
K. Fukada, Kouji Matumoto, F. Takakura, Masaharu Yamaki, Hiroyuki Sato, K. Okochi, Y. Maeda (2000)
Four putative subtypes of human parvovirus B19 based on amino acid polymorphism in the C‐terminal region of non‐structural proteinJournal of Medical Virology, 62
M. Osaki, K. Matsubara, T. Iwasaki, T. Kurata, H. Nigami, H. Harigaya, K. Baba (1999)
Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying diseaseAnnals of Hematology, 78
H. Matsui, M. Sugimoto, S. Tsuji, M. Shima, J. Giddings, A. Yoshioka (1999)
Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.Journal of pediatric hematology/oncology, 21 1
M. Anderson, P. Higgins, L. Davis, J. Willman, S. Jones, I. Kidd, J. Pattison, D. Tyrrell (1985)
Experimental parvoviral infection in humans.The Journal of infectious diseases, 152 2
A. Eis-Hübinger, U. Sasowski, H. Brackmann, R. Kaiser, B. Matz, K. Schneweis (1996)
Parvovirus B19 DNA Is Frequently Present in Recombinant Coagulation Factor VIII ProductsThrombosis and Haemostasis, 76
J. Saldanha, P. Minor (1996)
Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufactureBritish Journal of Haematology, 93
M. Blundell, C. Beard, C. Astell (1987)
In vitro identification of a B19 parvovirus promoter.Virology, 157 2
G. Nigro, V. Bastianon, V. Colloridi, F. Ventriglia, P. Gallo, G. d’Amati, W. Koch, S. Adler (2000)
Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 31 1
T. Weimer, S. Streichert, C. Watson, A. Gröner (2001)
High‐titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionationTransfusion, 41
O. Corsi, A. Azzi, M. Morfini, R. Fanci, P. Ferrini (1988)
Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentratesJournal of Medical Virology, 25
Karetnyi Karetnyi, Beck Beck, Markin Markin (1999)
Human parvovirus B19 infection in acute fulminant liver failure.Arch Virol, 144
J. Aubin, C. Defer, M. Vidaud, M. Montreuil, B. Flan (2000)
Large–Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for FractionationVox Sanguinis, 78
Ulrike Koenigbauer, T. Eastlund, J. Day (2000)
Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent‐treated pooled plasmaTransfusion, 40
M. Hino, O. Ishiko, K. Honda, T. Yamane, K. Ohta, T. Takubo, N. Tatsumi (2000)
Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgeryBritish Journal of Haematology, 108
Engelfriet Engelfriet, Reesink Reesink, Hernandez Hernandez (2002)
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology.Vox Sang, 82
E. Santagostino, P. Mannucci, A. Gringeri, A. Azzi, M. Morfini, R. Musso, R. Santoro, M. Schiavoni (1997)
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilizationTransfusion, 37
Y. Yoto, T. Kudoh, K. Haseyama, N. Suzuki, Shigeru Chiba (1996)
Human parvovirus B19 infection associated with acute hepatitisThe Lancet, 347
BACKGROUND: Human parvovirus B19 (B19) DNA can be frequently detected in plasma‐derived coagulation factor concentrates. The production of some clotting factor products includes heat treatment steps for virus inactivation, but the effectiveness of such steps for B19 inactivation is unclear. Moreover, detailed transmission case reports including DNA sequence analysis and quantification of B19 DNA from contaminated heat‐treated blood components have not been provided so far. Therefore, the correlation between B19 DNA in blood components and infectivity remains unclear. STUDY DESIGN AND METHODS: Asymptomatic B19 infections of two patients with hemophilia A were detected by anti‐B19 seroconversion after administration of B19‐contaminated heat‐treated clotting factors. The suitability of nucleic acid sequence analysis for confirmation of B19 transmission was investigated. Furthermore, the B19 DNA level in blood components was determined and the drug administration was reviewed to calculate the amount of inoculated B19 DNA. RESULTS: Both B19 transmissions from clotting factor products could be confirmed by identical nucleic acid sequences of virus DNA from patients and blood components while sequences from unrelated controls could be differentiated. One patient received, for 4 days, a total of 180 mL vapor heat‐treated prothrombin complex concentrate containing 8.6 × 106 genome equivalents per mL of B19 DNA. The other patient received 966 mL of low‐contamination (4.0 × 103 genome equivalents/mL) dry heat‐treated FVIII concentrate over a period of 52 days. CONCLUSION: B19 transmissions can be confirmed by nucleic acid sequencing. However, due to the low variability of the B19 genome, a large part of the B19 genome must be analyzed. The transmissions show that the applied heat treatment procedures were not sufficient to inactivate B19 completely.
Transfusion – Wiley
Published: Nov 1, 2002
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.